Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 3/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.45 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21639161 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL29529350 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL29529103 | 0.88 | MDM4 (0.45) | MDM4TP53CASP3MDM2HDAC1 | |
| SCHEMBL31754286 | 0.86 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL25354133 | 0.85 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL25361169 | 0.85 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL25354137 | 0.85 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL24633759 | 0.85 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL2310084 | 0.85 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 | |
| SCHEMBL2310091 | 0.85 | MDM4 (0.52) | MDM4TP53CASP3MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORPORATION (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3604326-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | VIP, NPPA, NGLY1 | MDM4 4154/4885TP53 1409/4885CASP3 2306/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | MDM4 4154/4885TP53 1409/4885CASP3 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.